Publications

Geng H, Brennan S, Milne TA, Chen W-Y, Li Y, Hurtz C, Kweon S-M, Zickl L, Shojaee S, Neuberg D et al..  2012.  Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.. Cancer Discov. 2(11):1004-23.

Sagardoy A, Martinez-Ferrandis JI, Roa S, Bunting KL, Aznar MAngela, Elemento O, Shaknovich R, Fontán L, Fresquet V, Perez-Roger I et al..  2013.  Downregulation of FOXP1 is required during germinal center B-cell function.. Blood. 121(21):4311-20.

Lin P-C, Chiu Y-L, Banerjee S, Park K, Mosquera JMiguel, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H et al..  2013.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.. Cancer Res. 73(3):1232-44.

Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM et al..  2013.  EZH2 mutations are frequent and represent an early event in follicular lymphoma.. Blood. 122(18):3165-8.

Chaudhri VK, Salzler GG, Dick SA, Buckman MS, Sordella R, Karoly ED, Mohney R, Stiles BM, Elemento O, Altorki NK et al..  2013.  Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor.. Mol Cancer Res. 11(6):579-92.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S et al..  2014.  Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.. Cancer Discov. 4(9):1022-35.

Wen D, Banaszynski LA, Liu Y, Geng F, Noh K-M, Xiang J, Elemento O, Rosenwaks Z, C Allis D, Rafii S.  2014.  Histone variant H3.3 is an essential maternal factor for oocyte reprogramming.. Proc Natl Acad Sci U S A. 111(20):7325-30.

Rickman KA, Lach FP, Abhyankar A, Donovan FX, Sanborn EM, Kennedy JA, Sougnez C, Gabriel SB, Elemento O, Chandrasekharappa SC et al..  2015.  Deficiency of UBE2T, the E2 Ubiquitin Ligase Necessary for FANCD2 and FANCI Ubiquitination, Causes FA-T Subtype of Fanconi Anemia.. Cell Rep. 12(1):35-41.

Rickman KA, Lach FP, Abhyankar A, Donovan FX, Sanborn EM, Kennedy JA, Sougnez C, Gabriel SB, Elemento O, Chandrasekharappa SC et al..  2015.  Deficiency of UBE2T, the E2 Ubiquitin Ligase Necessary for FANCD2 and FANCI Ubiquitination, Causes FA-T Subtype of Fanconi Anemia.. Cell Rep. 12(1):35-41.

Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I et al..  2015.  The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.. Nat Med. 21(10):1199-208.

Durrans A, Gao D, Gupta R, Fischer KR, Choi H, Rayes TEl, Ryu S, Nasar A, Spinelli CF, Andrews W et al..  2015.  Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC.. PLoS One. 10(6):e0129123.

Durrans A, Gao D, Gupta R, Fischer KR, Choi H, Rayes TEl, Ryu S, Nasar A, Spinelli CF, Andrews W et al..  2015.  Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC.. PLoS One. 10(6):e0129123.

Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G et al..  2015.  Integrative Clinical Genomics of Advanced Prostate Cancer.. Cell. 162(2):454.

Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G et al..  2015.  Integrative Clinical Genomics of Advanced Prostate Cancer.. Cell. 162(2):454.

Alinari L, Mahasenan KV, Yan F, Karkhanis V, Chung J-H, Smith EM, Quinion C, Smith PL, Kim L, Patton JT et al..  2015.  Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.. Blood. 125(16):2530-43.

Alinari L, Mahasenan KV, Yan F, Karkhanis V, Chung J-H, Smith EM, Quinion C, Smith PL, Kim L, Patton JT et al..  2015.  Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.. Blood. 125(16):2530-43.

Alinari L, Mahasenan KV, Yan F, Karkhanis V, Chung J-H, Smith EM, Quinion C, Smith PL, Kim L, Patton JT et al..  2015.  Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.. Blood. 125(16):2530-43.

Choi H, Sheng J, Gao D, Li F, Durrans A, Ryu S, Lee SB, Narula N, Rafii S, Elemento O et al..  2015.  Transcriptome analysis of individual stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model.. Cell Rep. 10(7):1187-201.

Gori JL, Butler JM, Chan Y-Y, Chandrasekaran D, Poulos MG, Ginsberg M, Nolan DJ, Elemento O, Wood BL, Adair JE et al..  2015.  Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells.. J Clin Invest. 125(3):1243-54.

Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, Roper J, Chio IIn Christi, Giannopoulou EG, Rago C et al..  2015.  Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.. Science. 350(6266):1391-6.

Page DB, Yuan J, Redmond D, Y Wen H, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C et al..  2016.  Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.. Cancer Immunol Res. 4(10):835-844.

Allen JE, C Kline LB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A et al..  2016.  Discovery and clinical introduction of first-in-class imipridone ONC201.. Oncotarget. 7(45):74380-74392.